Trader’s Watch List: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Chesapeake Energy Corporation (NYSE:CHK), Envivio, Inc. (NASDAQ:ENVI), Mannatech, Incorporated (NASDAQ:MTEX), Endocyte, Inc. (NASDAQ:ECYT)

Technology Stocks News 13

Amicus Therapeutics (NASDAQ:FOLD) COO Bradley L. Campbell unloaded 18,750 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $5.40, for a total transaction of $101,250.00. Following the completion of the transaction, the chief operating officer now directly owns 200,000 shares in the company, valued at approximately $1,080,000. Amicus Therapeutics, Inc. (NASDAQ:FOLD) belongs to Healthcare sector. Its weekly performance is 22.68%. On last trading day company shares ended up $5.41. Amicus Therapeutics, Inc. (NASDAQ:FOLD) distance from 50-day simple moving average (SMA50) is 42.50%.

Chesapeake Energy Corporation (NYSE:CHK) today announced that Brad Sylvester will join Chesapeake as Vice President – Investor Relations and Communications. Sylvester joins Chesapeake from Southwestern Energy Company. He will report to Chesapeake’s Chief Financial Officer, Nick Dell’Osso. Chesapeake Energy Corporation (NYSE:CHK) shares moved up 0.49% in last trading session and ended the day at $26.46. CHK Gross Margin is 88.70% and its return on assets is 2.00%. Chesapeake Energy Corporation (NYSE:CHK) quarterly performance is 0.38%.

Envivio Inc. (NASDAQ:ENVI), a leading provider of software-based video processing and delivery solutions, today announced that it will release its financial results for the second quarter ended July 31, 2014 after the market closes on Wednesday, September 3rd, 2014. On 21 August, Envivio, Inc. (NASDAQ:ENVI) shares fell -1.83% and was closed at $1.88. ENVI EPS growth in last 5 year was 5.30%. Envivio, Inc. (NASDAQ:ENVI) year to date (YTD) performance is -44.85%.

Mannatech Inc. (NASDAQ:MTEX) CEO Robert A. Sinnott purchased 3,995 shares of the company’s stock in a transaction that occurred on Tuesday, August 19th. The shares were purchased at an average cost of $12.48 per share, with a total value of $49,857.60. Following the completion of the acquisition, the chief executive officer now directly owns 1,666 shares of the company’s stock, valued at approximately $20,792. Mannatech, Incorporated (NASDAQ:MTEX) ended the last trading day at $12.47. Company weekly volatility is calculated as 2.30%and price to cash ratio as 1.65. Mannatech, Incorporated (NASDAQ:MTEX) showed a weekly performance of 0.89%.

Lifshitz & Miller announces that a class action was filed in the United States District Court for the Southern District of Indiana alleging that Endocyte, Inc. (NASDAQ:ECYT) issued false and misleading statements between March 21, 2014 and May 2, 2014. Specifically, on May 2, 2014, Endocyte disclosed that VYNFINIT was found ineffective in the treatment of platinum-resistant ovarian cancer, based on certain testing methods known as response evaluation criteria in solid tumors, or “RECIST.” Endocyte, Inc. (NASDAQ:ECYT) shares fell -2.62% in last trading session and ended the day on $6.31. ECYT return on assets is 7.50%. Endocyte, Inc. (NASDAQ:ECYT) quarterly performance is -2.17%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone